| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.blissgvs.com | |
| Market Cap | 1,160.50 Cr. | |
| Enterprise Value(EV) | 1,084.74 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 8.40 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 13.20 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 91.73 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 1.21 | Calculated using Price: 110.85 |
| Dividend Yield | 0.45 | Period Ending 2023-03 |
| No. of Shares Subscribed | 10.47 Cr. | 104,690,822 Shares |
| FaceValue | 1 | |
| About Bliss GVS Pharma Ltd. | ||
| It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company's most unique product is ‘Today Vaginal Contraceptive', a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products. | ||
| 1 Day |
|
-1.07% |
| 1 Week |
|
-3.56% |
| 1 Month |
|
+1.14% |
| 3 Month |
|
-15.24% |
| 6 Month |
|
+24.30% |
| 1 Year |
|
+48.77% |
| 2 Year |
|
+33.43% |
| 5 Year |
|
-37.93% |
| 10 Year |
|
+135.31% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 19.74 | 26.73 | 25.06 | 17.34 | 21.43 | 13.79 | 9.64 | 2.88 | 9.11 | |
| Return on Capital Employed (%) | 23.57 | 32.07 | 31.06 | 24.61 | 26.58 | 17.02 | 12.49 | 6.37 | 12.22 | |
| Return on Assets (%) | 9.01 | 13.04 | 11.88 | 9.42 | 14.35 | 9.86 | 7.03 | 2.12 | 6.78 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 337 | 413 | 487 | 536 | 646 | 736 | 808 | 819 | 884 | 930 | |
| Non Curr. Liab. | 68 | 50 | 33 | 13 | 38 | 46 | 45 | 29 | 43 | 62 | |
| Curr. Liab. | 243 | 379 | 437 | 299 | 207 | 231 | 204 | 233 | 193 | 172 | |
| Minority Int. | 15 | 33 | 66 | 11 | 14 | 15 | 20 | 28 | 34 | 33 | |
| Equity & Liab. | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,197 | |
| Non Curr. Assets | 245 | 291 | 457 | 170 | 211 | 257 | 312 | 332 | 456 | 451 | |
| Curr. Assets | 417 | 583 | 566 | 690 | 693 | 770 | 765 | 777 | 697 | 747 | |
| Misc. Exp. not W/O | 0 | ||||||||||
| Total Assets | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,154 | 1,197 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 757 | |
| Other Income | 20 | 24 | 13 | 27 | 38 | 39 | 22 | 31 | 18 | 26 | |
| Total Income | 427 | 571 | 811 | 841 | 936 | 728 | 599 | 779 | 769 | 783 | |
| Total Expenditure | -304 | -391 | -596 | -618 | -741 | -566 | -471 | -629 | -634 | -628 | |
| PBIDT | 124 | 180 | 215 | 224 | 195 | 163 | 129 | 150 | 135 | 155 | |
| Interest | -16 | -19 | -20 | -23 | -4 | -8 | -7 | -5 | -10 | -10 | |
| Depreciation | -11 | -13 | -20 | -21 | -9 | -13 | -17 | -17 | -19 | -24 | |
| Taxation | -35 | -48 | -63 | -57 | -55 | -34 | -30 | -31 | -29 | -30 | |
| Exceptional Items | -34 | -13 | -74 | ||||||||
| PAT | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 90 | |
| Minority Interest | -1 | -18 | -31 | -30 | -3 | 2 | -5 | -8 | -6 | -2 | |
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 60 | 82 | 82 | 59 | 124 | 97 | 68 | 15 | 71 | 88 | |
| Adjusted EPS | 6 | 8 | 8 | 6 | 12 | 9 | 7 | 1 | 7 | 8 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | 34 | |
| Cash Fr. Inv. | -11 | -29 | -50 | -231 | 50 | -74 | -48 | -47 | -93 | -8 | |
| Cash Fr. Finan. | -8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | -25 | |
| Net Change | 22 | -33 | 23 | 48 | -8 | -17 | -8 | -4 | 19 | 2 | |
| Cash & Cash Eqvt | 50 | 5 | 28 | 47 | 37 | 15 | 15 | 13 | 22 | 25 |
|
Wed, 10 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Please find enclosed herewith a certificate received from Link Intime India Private Limited Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 for the quarter ended March 31 2024. |
|
Wed, 10 Apr 2024
Compliance Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Period April 01 2023 To March 31 2024 Please find enclosed herewith the Compliance Certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 for the period April 01 2023 to March 31 2024. |
|
Fri, 29 Mar 2024
Closure of Trading Window This is to inform you that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 (including any stautory modification(s) or re-enactment(s) thereof for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ("the Company")shall remain closed for all the Deignated Persons and their immediate relatives of the Company with effect from April 01 2024 till completion of 48 hours after the announcement of the Audited Financial Results for the financial year ended March 31 2024. |
| Thu, 18 Apr 2024 |
Making Higher Highs for 2 Days
|
High Decrease in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
Close Below Last Week Low
|
